诊断前不确定潜能的克隆性造血与癌症患者预后的关联
研究基于英国生物银行2006至2022年63 486例癌症患者的前瞻性队列,评估诊断前不确定潜能的克隆性造血(CHIP)与生存的关联。诊断前CHIP组2860例,对照组60 626例;中位随访4.2年,CHIP组全因死亡风险(HR 1.18,95%CI 1.11-1.25)和癌症特异性死亡风险(HR 1.17,95%CI 1.09-1.25)均高于对照组。
要点
- 诊断前CHIP与癌症患者全因死亡(HR 1.18)和癌症特异性死亡(HR 1.17)风险升高相关。
- 骨髓增殖性肿瘤、多发性骨髓瘤、乳腺癌、非霍奇金淋巴瘤和急性髓系白血病/骨髓增生异常综合征中该关联显著。
- TET2、SRSF2或JAK2突变的CHIP与全因死亡和癌症特异性死亡风险升高相关。
核心结论
- 诊断前CHIP与癌症患者全因死亡和癌症特异性死亡风险升高相关,提示对这类患者需扩展临床关注。
研究设计与样本
- 前瞻性队列研究,纳入英国生物银行2006至2022年63 486例癌症患者。
主要发现
- 诊断前CHIP组2860例,对照组60 626例;中位随访4.2年,CHIP组死亡1162例(癌症特异性死亡921例),对照组死亡17 825例(癌症特异性死亡14 785例)。
- 诊断前CHIP组全因死亡风险高于对照组(HR 1.18,95%CI 1.11-1.25)。
- 诊断前CHIP组癌症特异性死亡风险高于对照组(HR 1.17,95%CI 1.09-1.25)。
- 骨髓增殖性肿瘤、多发性骨髓瘤、乳腺癌、非霍奇金淋巴瘤和急性髓系白血病/骨髓增生异常综合征中,全因死亡和癌症特异性死亡均观察到显著关联。
- TET2、SRSF2或JAK2突变的CHIP与全因死亡和癌症特异性死亡风险升高相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clonal hematopoiesis of indeterminate potential (CHIP) might impair prognosis of several cancer types. Since previous studies predominantly focused on CHIP after cancer diagnosis, little is known about whether CHIP prior to cancer diagnosis predicts outcome. We performed a prospective cohort study, including 63 486 patients with cancer during 2006 to 2022 in the UK Biobank, to evaluate the association between pre-diagnostic CHIP and survival of cancer patients. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated using Cox regression models. We identified 2860 patients with cancer and pre-diagnostic CHIP, and 60 626 cancer patients without CHIP. During a median follow-up of 4.2 years, 1162 patients died in the CHIP group (921 cancer-specific deaths), and 17 825 in the reference group (14 785 cancer-specific deaths). Cancer patients with pre-diagnostic CHIP exhibited a higher rate of overall death (HR 1.18, 95% CI: 1.11-1.25) and cancer-specific death (HR 1.17, 95% CI: 1.09-1.25) compared with the reference group. A significant association of both overall death and cancer-specific death was observed for myeloproliferative neoplasms, multiple myeloma, breast cancer, non-Hodgkin lymphoma, and acute myeloid leukemia/myelodysplastic syndromes. The increased rate of both overall death and cancer-specific death was noted for CHIP with TET2, SRSF2, or JAK2 mutation. These findings suggested extended clinical awareness in cancer patients with pre-diagnostic CHIP.
引用
- Liu X, Adami HO, Wästerlid T, et al. Association of Pre-Diagnostic Clonal Hematopoiesis of Indeterminate Potential With Prognosis Among Patients With Cancer. Am J Hematol. 2025. PMID: 40787700. doi:10.1002/ajh.70028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。